- Matinas Biopharma (MTNB) Q2 results: Revenues: $0.09M (unch).
- Net loss: ($3.6M) (-0.8%); loss/share: ($0.03) (+25.0%); Quick Assets: $36.8M (+196.8%).
- The Company is on track to initiate an additional head-to-head comparative study of MAT9001 and Vascepa in Q1 2020.
- NIH-funded Phase 1/2 EnACT trial of MAT2203 in cryptococcal meningitis to commence in Q4 2019. Cumulative data is expected in H1 2021.
- Previously: Matinas Biopharma Holdings EPS beats by $0.01, beats on revenue (Aug. 13)
Matinas Bio beats Q2 consensus
Recommended For You
More Trending News
About MTNB Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
MTNB | - | - |
Matinas BioPharma Holdings, Inc. |